Win for Severe MASH Drug; Antidepressant for IBS; Advances in Autoimmune Hepatitis

(MedPage Today) -- In patients with severe metabolic dysfunction-associated steatohepatitis (MASH), the investigational drug efruxifermin significantly improved fibrosis without worsening MASH at 96 weeks versus placebo in the phase IIb SYMMETRY...